Baker Bros. Advisors Adds $86K in Skye Bioscience, Inc. ($SKYE)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baker Bros. Advisors increased its position in Skye Bioscience, Inc. ($SKYE) by 8.59% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,575,243 shares of Skye Bioscience, Inc. after buying 124,605 shares during the quarter. Baker Bros. Advisors's holdings in Skye Bioscience, Inc. were worth $1.09 million as of its most recent filing.
Skye Bioscience, Inc. Stock Down 61.0%
Shares of Skye Bioscience, Inc. ($SKYE) traded around $0.69 on Sunday, down 61.0% for the day.
Skye Bioscience, Inc. Earnings
Analysts Set New Price Targets
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Get Skye Bioscience, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SKYE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.